Full Press Release Details
INmune Bio, Inc. Announces
Poster Presentation and Plenary Talk at the Alzheimer's Association International Conference 2021
Raton, FL, July 19, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology
company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today that
the Company will present a poster at the Alzheimer's Association International Congress 2021, which is being held in a hybrid format,
Denver and online, from July 26-30, 2021. In addition, Dr. Malu Tansey of the University of Florida College of Medicine and co-inventor
of XPro1595 (pegipanermin), will deliver a plenary talk, entitled, "Therapeutic Approaches Targeting Innate Immunity in
are very pleased to participate in this year's AAIC meeting and look forward to presenting a more detailed analysis of the positive
data from our recently completed Phase 1b study of XPro1595 in Alzheimer's," stated RJ Tesi, M.D., chief executive officer
of INmune Bio. "In that study, we were able to demonstrate that XPro1595 neutralizes soluble TNF and decreases biomarkers of neuroinflammation
across multiple measures and assays in Alzheimer's patients. The data suggest that decreasing neuroinflammation results in significant
improvements in biomarkers of neurodegeneration and synaptic function. We look forward to initiating a blinded, randomized Phase 2 study
by the end of this year as we continue to develop and advance novel therapeutics targeting dysfunction of the innate immune system."
of the presentation are as follows:
1b study of XPro1595 in Alzheimer's patients with biomarkers of inflammation
Barnum, PhD, Head of Neurosciences, INmune Bio, Inc.
-12:00noon MT (9am-1pm ET)
of the plenary talk are as follows:
Malu G. Tansey, Norman and Susan Fixel Professor of Neuroscience and Neurology, Co-Director Center for Translational Research in Neurodegenerative
Disease and the Parkinson's Foundation Research Center, Department of Neurology, University of Florida College of Medicine
Approaches Targeting Innate Immunity in AD
MT (5:00pm-6:00pm ET)
Alzheimer's Association International Conference brings together the world's leading basic scientists, clinical researchers,
early career investigators, clinicians and the care research community to share breaking research discoveries that will lead to methods
of prevention and treatment and improvements in diagnosis for Alzheimer's disease.
XPro1595 (pegipanermin)
is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from
approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without
affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer's
and other neurodegenerative diseases by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation
in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio's
Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the
innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology
to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently
being developed for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's and Treatment Resistant Depression
(XPro1595), and NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's
NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine
approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation with components of the
innate immune system. To learn more, please visit www.inmunebio.com.
about Forward-Looking Statements
trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press
release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained
herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain
events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and
uncertainties. INB03 , Quellor , XPro1595, LIVNate , and INKmune are still in clinical trials or preparing to
start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results
will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are
not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability
of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies
and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing
and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings
with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly
Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may arise after the date of this release.
LifeSci Communications